China extends anti-dumping duties on stainless steel imports
China's Ministry of Commerce announced Monday it will extend anti-dumping duties on specific stainless steel imports from the European Union, United K...
A new long-acting preventive HIV drug, lenacapavir, could be available in the world’s poorest countries by late 2025 or early 2026, according to Hui Yang, head of supply operations at the Global Fund to Fight AIDS, Tuberculosis and Malaria.
According to Hui Yang of the Global Fund, lenacapavir, a new long-acting preventive HIV drug, may be available in the world’s poorest countries by late 2025 or early 2026.
The timeline depends on regulatory approvals from authorities like the U.S. Food and Drug Administration and the World Health Organization, Yang said.
Lenacapavir is already approved as a treatment for multi-drug resistant HIV in the U.S., where it costs around $42,250 for the first year of therapy. Recent clinical trials have also demonstrated its effectiveness in preventing HIV infection, prompting Gilead Sciences to seek global approval for this new use.
Yang stressed the need for low and middle-income countries to have timely access to the drug, stating, "We don't want...low and low-middle income countries to wait, to be at the back of the line." This issue has long been a barrier in the fight against HIV.
To ensure affordable access, the Global Fund is collaborating with the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), along with funding from the Children’s Investment Fund Foundation and the Bill & Melinda Gates Foundation. Together, they aim to provide lenacapavir to at least two million people in participating countries over three years.
In October, Gilead signed agreements with six generic drugmakers to produce lenacapavir more affordably for 120 low and middle-income countries. However, the deal faced criticism for excluding some regions, particularly in Latin America. Yang stated that while no agreements have been finalized with Gilead or the generic producers, they will work with all involved companies.
The U.S. economy faces a 40% risk of recession in the second half of 2025, JP Morgan analysts said on Wednesday, citing rising tariffs and stagflation concerns.
China has ramped up efforts to protect communities impacted by flood control measures, introducing stronger compensation policies and direct aid from the central government.
Severe rain in Venezuela has caused rivers to overflow and triggered landslides, sweeping away homes and collapsing a highway bridge, with five states affected and no casualties reported so far.
A malfunction in the radar transmission system at the Area Control Center in Milan suspended more than 300 flights at the weekend, across northwest Italy since Saturday evening according to Italy's air traffic controller Enav (National Agency for Flight Assistance).
Thousands of protesters rallied in Bangkok on Saturday, demanding Prime Minister Paetongtarn Shinawatra resign as political and economic tensions mount.
France will impose its toughest outdoor smoking restrictions starting Monday, banning smoking at beaches, parks, playgrounds, and bus stops.
Scientists in Australia and the U.S. have developed an AI tool that could transform cancer care by revealing the hidden diversity of tumour cells and guiding more targeted therapies.
Singapore has launched its largest-ever study on paediatric food allergies, aiming to better understand and address the growing burden of allergic reactions among children.
Bill Gates says his foundation will not compensate for funding shortfalls caused by U.S. and UK aid cuts to global vaccination efforts, warning of rising child mortality as a result.
The world is facing a health financing emergency as global health investment risks falling to its lowest level in a decade, the World Health Organization (WHO) warned.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment